Patents Examined by Geetha P. Bansal
  • Patent number: 6818213
    Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: November 16, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
  • Patent number: 6805862
    Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglio-side-specific antibody attached to a carrier.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 2004
    Assignee: Sloan-Kattering Institute For Cancer Research
    Inventors: Paul B. Chapman, Alan N. Houghton
  • Patent number: 6696416
    Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis . The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: February 24, 2004
    Assignee: Angstrom Pharmaceuticals, Inc.
    Inventors: Andrew P. Mazar, Terence R. Jones
  • Patent number: 6692746
    Abstract: Superantigens, including Staphylococcal enterotoxins streptococcal pyrogenic exotoxins (SpE's), biologically active fragments and homologues thereof and fission proteins of the native superantigens, homologues and fragments, are useful agents for killing tumor cells, enhancing antitumor immunity and for treating tumors in a tumor-bearing subject. In particular, a subject having a tumor is treated with a tumoricidally effective amount of a superantigen, such as a SE or SpE, or a biologically active homologue thereof, fusion protein thereof or a fusion protein of the homologue. These agents stimulate T cells, leading to increased antitumor immunity and killing of tumor cells.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: February 17, 2004
    Inventors: David S. Terman, Jay L. Stone
  • Patent number: 6683156
    Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the, bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: January 27, 2004
    Assignee: University of South Florida
    Inventor: Siamak Tabibzadeh
  • Patent number: 6669941
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: December 30, 2003
    Assignee: Biogen, Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Patent number: 6610659
    Abstract: The use of cognate heat shock protein 70-peptide complex to elicit an immune response against cancer and viral, bacterial and other infectious agents.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: August 26, 2003
    Assignee: Mount Sinai School of Medicine of New York University
    Inventor: Srivastava K. Pramod
  • Patent number: 6558900
    Abstract: A cell-free system based on the cytosol of normally growing cells, which reproduces measurable aspects of the apoptotic program, is provided. The apoptotic program is initiated by addition of DATP in the specific exemplification of the HeLa 100,000×g supernatant. Fractionation of the cytosol yielded a 15 kDa protein, identified by absorption spectrum and protein sequence as cytochrome c, that is required for in vitro apoptosis. Elimination of cytochrome c from cytosol by immunodepletion or inclusion of sucrose to stabilize mitochondria during cytosol preparation, diminished the apoptotic activity. Addition of exogenous cytochrome c to cytochrome c-depleted extracts restored apoptotic activity. Cells undergoing apoptosis in vivo showed increased release of cytochrome c to their cytosol, suggesting that mitochondria may function in apoptosis by releasing cytochrome c.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: May 6, 2003
    Assignee: Emory University
    Inventors: Xiaodong Wang, Xuesong Liu
  • Patent number: 6512097
    Abstract: This invention provides novel chimeric molecules that specifically binds a tumor cell bearing a c-erbB-2. The chimeric molecules comprise an effector molecule attached to a C6 antibody that specifically binds to c-erbB-2. The chimeric molecules can specifically target and deliver effector molecules to cells overexpressing c-erb-B2.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 28, 2003
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Robert Schier
  • Patent number: 6500931
    Abstract: Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: December 31, 2002
    Assignee: Medarex, Inc.
    Inventors: Philip R. Tempest, William J. Harris, Frank J. Carr
  • Patent number: 6475490
    Abstract: The invention relates to methods and compositions for the promotion of tissue repair. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, uncomplexed or complexed noncovalently with antigenic molecules, are disclosed. Therapeutic methods for administering the hsp-containing compositions are disclosed. The disclosed methods are useful for promoting repair of tissues that were disrupted by a variety of causes including trauma (e.g., surgery, injury or burns) or disease or disorder (e.g., atherosclerosis and multiple sclerosis).
    Type: Grant
    Filed: October 19, 1998
    Date of Patent: November 5, 2002
    Assignee: Fordham University
    Inventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
  • Patent number: 6468540
    Abstract: Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the Hsp70-peptide, Hsp90-peptide and gp96-peptide complexes.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: October 22, 2002
    Assignee: Mount Sinai School of Medicine of New York University
    Inventor: Pramod K. Srivastava
  • Patent number: 6461615
    Abstract: The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 8, 2002
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Patent number: 6458939
    Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that ate differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: October 1, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Andrew W. Shyjan
  • Patent number: 6458354
    Abstract: Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 1, 2002
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Sean O'Herrin, Michael S. Lebowitz, Abdel Hamad
  • Patent number: 6458561
    Abstract: The invention provides a nucleic acid molecule which encodes the human NIM1 kinase. It also provides for the use of the nucleic acid molecule, fragments, variants and complements thereof and of the protein, portions thereof and antibodies thereto for characterization, diagnosis, evaluation, treatment, or prevention of disorders associated with expression. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic organism or model system.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: October 1, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Olga Bandman, Angela Molteni, Paola Magnaghi, Roberta Bosotti, Emanuela Scacheri, Antonella Isacchi, David M. Hodgson
  • Patent number: 6455280
    Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: September 24, 2002
    Assignee: Genset S.A.
    Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel
  • Patent number: 6455048
    Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: September 24, 2002
    Assignee: Fordham University
    Inventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
  • Patent number: 6455503
    Abstract: Disclosed is a family of vaccines that contain stress protein-peptide complexes which when administered to a mammal are operative to initiate in the mammal a cytotoxic T cell response against cells infected with a preselected intracellular pathogen. Also disclosed are methodologies for preparing and administering vaccines containing such stress protein-peptide complexes.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: September 24, 2002
    Assignee: Mount Sinai School of Medicine of New York University
    Inventor: Pramod K. Srivastava
  • Patent number: 6451316
    Abstract: The present invention provides methods for generating antigen-reactive T cells in vitro comprising priming immune cells and incubating the primed immune cells in vitro with a non-covalent complex of an heat shock protein and an antigenic molecule. The present invention further relates to methods for generating antigen-reactive CD4+ T cells for immunotherapy. Methods and compositions are also disclosed for the treatment and prevention of cancer or infectious disease in a subject comprising administering to the subject MHC matched antigen-reactive T cells that are generated in vitro by the present methods.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: September 17, 2002
    Assignee: University of Conneticut Health Center
    Inventor: Pramod K. Srivastava